Clinical trial of postoperative adjuvant chemotherapy with carboplatin/paclitaxel according to the results of collagen gel droplet embedded culture drug sensitivity test (CD-DST) in completely resected non-small-cell lung cancer

Clinical trial of postoperative adjuvant chemotherapy with carboplatin/paclitaxel according to the results of collagen gel droplet embedded culture drug sensitivity test (CD-DST) in completely resected non-small-cell lung cancer - Postoperative adjuvant chemotherapy according to the results of drug sensitivity test in non-small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000210

Enrollment

150

Registered

2005-09-15

Start date

2005-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Completely resected p-IB-IIIA non-small cell lung cancer

Interventions

Adjuvant chemotherapy with carboplatin (6AUC) + paclitaxel (70mg/m2 x 3 week) x 4 courses is given to p-stage IB-IIIA non-small cell lung cancer patients whose tumors show moderate or high sensitivity

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Pathologically proven non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma). 2, p-stage IB-IIIA. 3, No previous chemotherapy. 4, ECOG Performance Status (PS) 0 - 1. 5, Adequate major organ function. 6, No active other malignancy. 7, Written informed consent.

Exclusion criteria

Exclusion criteria: 1, Heart diseases required treatment. 2, Myocardial infarction within 6 months. 3, Liver cirrhosis. 4, Symptomatic interstitial pneumonia or pulmonary fibrosis proven in the chest X-ray. 5, Active bowel hemorrhage required repeated transfusion. 6, Uncontrollable diabetes mellitus. 7, Ileus or subileus. 8, Active infection. 9, Peripheral neuropathy. 10, Psychological disorder required medication. 11, Drug allergy against cremophor EL(polyoxethylated castor oil). 12, During pregnancy or lactation. 13, Inadequate condition diagnosed by the primary physician.

Design outcomes

Primary

Measure	Time frame
Disease free survival	—

Secondary

Measure	Time frame
Overall Survival Toxicity	—

Countries

Japan

Contacts

Public ContactMasayoshi Inoue

Osaka University Graduate School of Medicine Department of General Thoracic Surgery

mi@thoracic.med.osaka-u.ac.jp06-6879-3152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026